

09/19/00
JCS13 U.S. PTO

9-20-00

A

Please type a plus sign (+) inside this box → ☒

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. MIT 6962 CIP(2)
First Inventor or Application Identifier John T. Santini, Jr.
Title MICROCHIP DRUG DELIVERY DEVICES
Express Mail Label No. EL 381 203 534 US

APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 44]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 9]
4. Oath or Declaration [Total Pages 3]
 - a. ☒ Unexecuted
 - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement of Attorney (when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 [Copies of IDS Citations]
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ * Small Entity Statement(s) [Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)]
14. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. ☒ Other: Check for \$534.00

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: 09,022,322
Prior application information: Examiner A. Alanko Group / Art Unit: 1763

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon if the information has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

23579

or ☐ Correspondence address below

(Insert Customer No. or Attach bar code label here)

Name	Patreia L. Pabst				
	Arnall Golden & Gregory, LLP				
Address	2800 One Atlantic Center				
	1201 West Peachtree Street				
City	Atlanta	State	GA	Zip Code	30309-3450
Country	United States	Telephone	(404) 873-8794	Fax	(404) 873-8795

Name (Print/Type)	Kevin W. King	Registration No. (Attorney/Agent)	42,737
Signature	<i>Kevin W. King</i>	Date	September 19, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2000

Patent fees are subject to annual revision.
Small Entity payments must be supported by a small entity statement,
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

TOTAL AMOUNT OF PAYMENT (\$1068.00)

Complete if Known

Application Number	
Filing Date	September 19, 2000
First Named Inventor	John T. Santini, Jr.
Examiner Name	
Group / Art Unit	
Attorney Docket No.	MIT 6962 CIP(2)

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 01-2507
Deposit Account Name Arnall Golden & Gregory, LLP

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. ☒ Payment Enclosed:
☒ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 690	201 345	Utility filing fee	690.00
106 310	206 155	Design filing fee	
107 480	207 240	Plant filing fee	
108 690	208 345	Reissue filing fee	
114 150	214 75	Provisional filing fee	

SUBTOTAL (1) (\$690.00)

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
41	-20 = 21	x 18	= 378.00
Independent Claims	3	-3 = 3	x 0 = 0.00
Multiple Dependent			= 378.00

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 78	202 39	Independent claims in excess of 3
104 260	204 130	Multiple dependent claim, if not paid
109 78	209 39	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$378.00)

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet.	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 380	216 190	Extension for reply within second month	
117 870	217 435	Extension for reply within third month	
118 1,360	218 680	Extension for reply within fourth month	
128 1,850	228 925	Extension for reply within fifth month	
119 300	219 150	Notice of Appeal	
120 300	220 150	Filing a brief in support of an appeal	
121 260	221 130	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,210	241 605	Petition to revive - unintentional	
142 1,210	242 605	Utility issue fee (or reissue)	
143 430	243 215	Design issue fee	
144 580	244 290	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Petitions related to provisional applications	
126 240	126 240	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 690	246 345	Filing a submission after final rejection (37 CFR 1.129(a))	
149 690	249 345	For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (specify) _____
**Represents the difference between the fee for a ☐ month extension of time and a ☐ month extension of time.

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Typed or Printed Name Kevin W. King

Signature Kevin W. King

Date 9/19/00

Complete (if applicable)

Reg. Number 42,737

Deposit Account User ID 01-2507

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John T. Santini, Jr., Michael J. Cima, and Robert S. Langer

Serial No:

Express Mail Label No.:
EL 381 203 534 US

Filed: September 19, 2000

Date of Deposit:
September 19, 2000

For: *MICROCHIP DRUG DELIVERY DEVICES*

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

**EXPRESS MAIL TRANSMITTAL LETTER
FOR PATENT APPLICATION WITH CERTIFICATE OF MAILING**

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10,
John T. Santini, Jr., Michael J. Cima, and Robert S. Langer enclose for filing the patent
application entitled "MICROCHIP DRUG DELIVERY DEVICES " which is a continuation-in-
part of U.S. application Serial No. 09/022,322 filed February 11, 1998, which will be U.S. Patent
No. 6,123,861, which is a continuation-in-part of U.S. application Serial No. 08/675,375 filed
July 2, 1996, now U.S. Patent No. 5,797,898. The application includes 1 page of abstract, 37
pages of specification, 6 pages of claims, 9 sheets of drawings (8 formal, 1 informal), and an
unexecuted declaration. A check in the amount of \$534.00.00 to cover one half of the filing fee
is enclosed.

"MICROCHIP DRUG DELIVERY DEVICES"

By: John T. Santini, Jr., Michael J. Cima, and Robert S. Langer

Filed: September 19, 2000

EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION

Express Mail Label No. EL 381 203 534 US

The Commissioner is hereby authorized to charge Deposit Order Account No. 01-2507 in the amount of \$534.00, which represents the difference between the filing fee of \$1,068.00 for a large entity and the enclosed check for \$534.00. An executed Declaration, Assignment, and Verified Statement Claiming Small Entity Status will be submitted shortly.

This application is being filed on September 19, 2000, by mailing the application to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10. The Express Mail Label No. EL 381 203 534 US appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(b).

The Commissioner is hereby authorized to charge any other fees that may be required, or credit any overpayment, to Deposit Order Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

"MICROCHIP DRUG DELIVERY DEVICES"

By: John T. Santini, Jr., Michael J. Cima, and Robert S. Langer

Filed: September 19, 2000


EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION

Express Mail Label No. EL 381 203 534 US

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3450

Respectfully submitted,




Kevin W. King
Reg. No. 42,737

Date: September 19, 2000

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, GA 30309-3450
(404) 873 8596
(404) 873-8597 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR §1.10

I hereby certify that this Utility Patent Application Transmittal under 37 CFR 1.53(b), and any documents referred to as attached therein, are being deposited with the United States Postal Service on this date, September 19, 2000, in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Mailing Label Number EL 381 203 534 US, addressed to Box Patent Application, the Assistant Commissioner for Patents, Washington, D.C. 20231.



Eva Mukasa

Date: September 19, 2000

MIT 6962 CIP(2)
20220/513

APPLICATION

FOR

UNITED STATES LETTERS PATENT

BY

JOHN T. SANTINI, JR.

MICHAEL J. CIMA

AND

ROBERT S. LANGER

FOR

MICROCHIP DRUG DELIVERY DEVICES

MICROCHIP DRUG DELIVERY DEVICES

Cross-Reference To Related Applications

This is a continuation-in-part of application Serial No. 09/022,322, filed
5 February 11, 1998, now U.S. Patent No. 6,123,861, which is a continuation-in-
part of application Serial No. 08/675,375, filed July 2, 1996, now U.S. Patent
No. 5,797,898.

Background Of The Invention

10 This invention relates to miniaturized drug delivery devices and more
particularly, to controlled time and rate release multi-welled drug delivery
devices.

Drug delivery is an important aspect of medical treatment. The efficacy
of many drugs is directly related to the way in which they are administered.
15 Some therapies require that the drug be repeatedly administered to the patient
over a long period of time. This makes the selection of a proper drug delivery
method problematic. Patients often forget, are unwilling, or are unable to take
their medication. Drug delivery also becomes problematic when the drugs are
too potent for systemic delivery. Therefore, attempts have been made to design
20 and fabricate a delivery device which is capable of the controlled, pulsatile or
continuous release of a wide variety of molecules including, but not limited to,
drugs and other therapeutics.

Controlled release polymeric devices have been designed to provide drug
release over a period of time via diffusion of the drug out of the polymer and/or
25 degradation of the polymer over the desired time period following
administration to the patient. However, these devices are relatively simple.

U.S. Patent No. 5,490,962 to Cima, *et al.* discloses the use of three
dimensional printing methods to make more complex devices which provide
release over a desired time frame, of one or more drugs. Although the general
30 procedure for making a complex device is described, specific designs are not

detailed.

U.S. Patent No. 4,003,379 to Ellinwood describes an implantable electromechanically driven device that includes a flexible retractable walled container, which receives medication from a storage area via an inlet and then dispenses the medication into the body via an outlet. U.S. Patent No. 4,146,029 and U.S. Patent No. 3,692,027 to Ellinwood disclose self-powered medication systems that have programmable miniaturized dispensing means. U.S. Patent No. 4,360,019 to Jassawalla discloses an implantable infusion device that includes an actuating means for delivery of the drug through a catheter. The actuating means includes a solenoid driven miniature pump. All of these devices include miniature power-driven mechanical parts that are required to operate in the body, i.e., they must retract, dispense, or pump. These are complicated and subject to breakdown. Moreover, due to complexity and size restrictions, they are unsuitable to deliver more than a few drugs or drug mixtures at a time.

It is therefore an object of the present invention to provide a multi-welled delivery device that is relatively simple to use and manufacture, but which is dependable and capable of delivering drugs or other molecules and can operate for weeks or years at a time.

It is another object of the present invention to provide such a device that provides the delivery of drugs or other molecules in a controlled manner, such as continuously or pulsatile, and which operates actively or passively.

It is a further object of the present invention to provide such a device that can hold many different drugs or other molecules of varying dosages and is small enough to be implanted, injected or swallowed, if desired.

It is another object of the present invention to provide methods of manufacture and use of such devices.

Summary Of The Invention

Microchip devices are provided for the release of molecules. The

devices include (1) a substrate comprised of two or more substrate portions bonded together, (2) at least two reservoirs in the substrate containing the molecules for release, and (3) a reservoir cap positioned on, or within a portion of, the reservoir and over the molecules, so that the molecules are controllably released from the device by diffusion through or upon disintegration of the reservoir caps. In a preferred embodiment, the substrate comprises an upper substrate portion adjacent the reservoir cap and a lower substrate portion distal the reservoir cap, such that a reservoir section in the upper substrate portion is in communication with a reservoir section in the lower substrate portion, the two reservoir sections forming a single reservoir which generally is larger than that which would be provided using the single substrate device.

In an alternative embodiment, an internal reservoir cap is interposed between a reservoir section of the upper substrate portion and a reservoir section of the lower substrate portion, wherein release of the molecules from the reservoir section in the lower substrate portion is controlled by diffusion through or disintegration of the internal reservoir cap. The internal reservoir cap can be disintegratable so that the two reservoir sections thereby form a single reservoir. In this alternative embodiment, the reservoir section of the lower substrate portion can contain molecules different in quantity, type, or both quantity and type, from the molecules contained in the reservoir section of the upper substrate portion.

In a preferred embodiment, the molecule to be delivered is a drug. The drug can be provided alone or in a release system, such as a biodegradable matrix, or in any other pharmaceutically acceptable carrier. Combinations of different drugs can be delivered in different reservoirs or even in different reservoir sections as in the embodiment containing internal reservoir caps. The reservoirs can contain multiple drugs or other molecules in variable dosages.

Methods for making these microchip devices are also provided. In preferred embodiments, reservoirs are etched into two or more substrate portions using either chemical (wet) etching or plasma (dry) etching techniques well

known in the field of microfabrication. Hundreds to thousands of reservoirs can be fabricated on a single substrate portion using these techniques. SOI techniques also can be adapted to make the reservoirs. The reservoir sections of the substrate portions are aligned and then the portions are bonded together. The reservoirs, or portions thereof, are filled either prior to or after the portions are bonded together.

Each of the reservoirs of a single microchip can contain different molecules and/or different amounts and concentrations, which can be released independently. The filled reservoirs can be capped with materials that passively disintegrate, materials that allow the molecules to diffuse passively out of the reservoir over time, or materials that disintegrate upon application of an electric potential. Release from an active device can be controlled by a preprogrammed microprocessor, remote control, or by biosensors.

Brief Description Of The Drawings

Figure 1 depicts a typical fabrication scheme for a passive delivery device.

Figure 2 depicts a typical fabrication scheme for an active delivery device.

Figure 3 depicts a typical device control circuitry flowsheet.

Figure 4 depicts a passive delivery device.

Figure 5 depicts an active delivery device.

Figure 6 depicts an active device including insulator overlayers.

Figures 7a-i are schematic views of several configurations of passive delivery devices.

Figures 8a-c are schematic views of several configurations of active delivery devices.

Figures 9a-e are cross-sectional schematic views of various embodiments of devices having substrates formed from two fabricated substrate portions which have been joined together.

Detailed Description Of The Invention

Microchip devices have been provided which can accurately deliver drugs and other molecules at defined rates and times according to the needs of the patient or other experimental system. As used herein, a "microchip" is a

5 miniaturized device fabricated using methods commonly applied to the manufacture of integrated circuits and MEMS (MicroElectroMechanical Systems) such as ultraviolet (UV) photolithography, reactive ion etching, and electron beam evaporation, as described, for example, by Wolf & Tauber, *Silicon Processing for the VLSI Era, Volume 1 - Process Technology* (Lattice

10 Press, Sunset Beach, CA, 1986); and Jaeger, *Introduction to Microelectronic Fabrication*, Volume V in The Modular Series on Solid State Devices (Addison-Wesley, Reading, MA, 1988), as well as MEMS methods that are not standard in making computer chips, including those described, for example, in Madou, Fundamentals of Microfabrication (CRC Press, 1997) and

15 micromolding and micromachining techniques known in the art. The microchips provide control over the rate the molecules are released as well as the time at which release begins. The time of release can be controlled passively or actively. The microchip fabrication procedure allows the manufacture of devices with primary dimensions (length of a side if square or rectangular, or

20 diameter if circular) ranging from less than a millimeter to several centimeters. A typical device thickness is 300 μm . However, the thickness of the device can vary from approximately 10 μm to several millimeters, depending on the device's application. Total device thickness and reservoir volume can also be

25 increased by bonding or attaching additional silicon wafers or other substrate materials to the fabricated microchip device. In general, changing the device thickness affects the maximum number of reservoirs that may be incorporated onto a microchip and the volume of each reservoir. *In vivo* applications of the device would typically require devices having a primary dimension of 2 cm or smaller. Devices for *in vivo* applications are small enough to be swallowed or

30 implanted using minimally invasive procedures. Smaller *in vivo* devices (on the

order of a millimeter) can be implanted using a catheter or other injectable means. Devices for *in vitro* applications have fewer size restrictions and, if necessary, can be made much larger than the dimension ranges for *in vivo* devices.

5 **I. Device Components and Materials**

Each device consists of a substrate, reservoirs, and a release system containing, enclosing, or layered with the molecules to be delivered. Devices which control the release time of the molecules may include reservoir caps. Active devices may include control circuitry and a power source.

10 **A. The Substrate**

The substrate contains the etched, molded, or machined reservoirs and serves as the support for the microchip. Any material which can serve as a support, is suitable for etching, molding, or machining, and is impermeable to the molecules to be delivered and to the surrounding fluids, for example, water, blood, electrolytes or other solutions, may be used as a substrate. Examples of substrate materials include ceramics, semiconductors, and degradable and non-degradable polymers. Biocompatibility of the substrate material is preferred, but not required. For *in vivo* applications, non-biocompatible materials may be encapsulated in a biocompatible material, such as poly(ethylene glycol) or polytetrafluoroethylene-like materials, before use. One example of a strong, non-degradable, easily etched substrate that is impermeable to the molecules to be delivered and the surrounding fluids is silicon. In another embodiment, the substrate is made of a strong material that degrades or dissolves over a period of time into biocompatible components. This embodiment is preferred for *in vivo* applications where the device is implanted and physical removal of the device at a later time is not feasible or recommended, for example, brain implants. An example of a class of strong, biocompatible materials are the poly(anhydride-co-imides) discussed by K.E. Uhrich *et al.*, "Synthesis and characterization of degradable poly(anhydride-co-imides)", *Macromolecules*, 28:2184-93 (1995).

30 The substrate can be formed of only one material or can be a composite

or multi-laminate material, e.g., several layers of the same or different substrate materials that are bonded together. Multi-portion substrates can include any number of layers of silicon, glasses, ceramics, semiconductors, metals, polymers, or other substrate materials. Two or more complete microchip devices also can be bonded together to form multi-portion substrate devices (see, e.g., Figures 9a-e).

B. Release System

The molecules to be delivered may be inserted into the reservoirs in their pure form, as a liquid solution or gel, or they may be encapsulated within or by a release system. As used herein, "release system" includes both the situation where the molecules are in pure form, as either a solid or liquid, or are in a matrix formed of degradable material or a material which releases incorporated molecules by diffusion out of or disintegration of the matrix. The molecules can be sometimes contained in a release system because the degradation, dissolution or diffusion properties of the release system provide a method for controlling the release rate of the molecules. The molecules can be homogeneously or heterogeneously distributed within the release system. Selection of the release system is dependent on the desired rate of release of the molecules. Both non-degradable and degradable release systems can be used for delivery of molecules. Suitable release systems include polymers and polymeric matrices, non-polymeric matrices, or inorganic and organic excipients and diluents such as, but not limited to, calcium carbonate and sugar. Release systems may be natural or synthetic, although synthetic release systems are preferred due to the better characterization of release profiles. The release system is selected based on the period over which release is desired, generally in the range of at least three to twelve months for *in vivo* applications. In contrast, release times as short as a few seconds may be desirable for some *in vitro* applications. In some cases, continuous (constant) release from a reservoir may be most useful. In other cases, a pulse (bulk) release from a reservoir may provide more effective results. Note that a single pulse from one reservoir can be transformed into

pulsatile release by using multiple reservoirs. It is also possible to incorporate several layers of a release system and other materials into a single reservoir to achieve pulsatile delivery from a single reservoir. Continuous release can be achieved by incorporating a release system that degrades, dissolves, or allows
5 diffusion of molecules through it over an extended period of time. In addition, continuous release can be simulated by releasing several pulses of molecules in quick succession.

The release system material can be selected so that molecules of various molecular weights are released from a reservoir by diffusion out or through the
10 material or degradation of the material. Biodegradable polymers, bioerodible hydrogels, and protein delivery systems are preferred for release of molecules by diffusion, degradation, or dissolution. In general, these materials degrade or dissolve either by enzymatic hydrolysis or exposure to water *in vivo* or *in vitro*, or by surface or bulk erosion. Representative synthetic, biodegradable polymers
15 include: poly(amides) such as poly(amino acids) and poly(peptides); poly(esters) such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone); poly(anhydrides); poly(orthoesters); poly(carbonates); and chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications
20 routinely made by those skilled in the art), copolymers and mixtures thereof. Representative synthetic, non-degradable polymers include: poly(ethers) such as poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers - poly(acrylates) and poly(methacrylates) such as methyl, ethyl, other alkyl, hydroxyethyl methacrylate, acrylic and methacrylic acids, and others
25 such as poly(vinyl alcohol), poly(vinyl pyrrolidone), and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose, and various cellulose acetates; poly(siloxanes); and any chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications
30 routinely made by those skilled in the art), copolymers and mixtures thereof.

C. Molecules to Be Released

Any natural or synthetic, organic or inorganic molecule or mixture thereof can be delivered. In one embodiment, the microchip is used to deliver drugs systemically to a patient in need thereof. In another embodiment, the construction and placement of the microchip in a patient enables the localized release of drugs that may be too potent for systemic delivery. As used herein, drugs are organic or inorganic molecules, including proteins, nucleic acids, polysaccharides and synthetic organic molecules, having a bioactive effect, for example, anaesthetics, vaccines, chemotherapeutic agents, hormones, metabolites, sugars, immunomodulators, antioxidants, ion channel regulators, and antibiotics. The drugs can be in the form of a single drug or drug mixtures and can include pharmaceutically acceptable carriers. In another embodiment, molecules are released *in vitro* in any system where the controlled release of a small (milligram to nanogram) amount of one or more molecules is required, for example, in the fields of analytic chemistry or medical diagnostics. Molecules can be effective as pH buffering agents, diagnostic agents, and reagents in complex reactions such as the polymerase chain reaction or other nucleic acid amplification procedures.

D. Reservoir Caps

In the passive timed release drug delivery devices, the reservoir caps are formed from a material that degrades or dissolves over time, or does not degrade or dissolve but is permeable to the molecules to be delivered. These materials are preferably polymeric materials. Materials can be selected for use as reservoir caps to give a variety of degradation rates or dissolution rates or permeabilities to enable the release of molecules from different reservoirs at different times and, in some cases, different rates. To obtain different release times (amounts of release time delay), caps can be formed of different polymers, the same polymer with different degrees of crosslinking, or a UV polymerizable polymer. In the latter case, varying the exposure of this polymer to UV light results in varying degrees of crosslinking and gives the cap material different

diffusion properties or degradation or dissolution rates. Another way to obtain different release times is by using one polymer, but varying the thickness of that polymer. Thicker films of some polymers result in delayed release time. Any combination of polymer, degree of crosslinking, or polymer thickness can be modified to obtain a specific release time or rate. In one embodiment, the release system containing the molecules to be delivered is covered by a degradable cap material which is nearly impermeable to the molecules. The time of release of the molecules from the reservoir will be limited by the time necessary for the cap material to degrade or dissolve. In another embodiment, the cap material is non-degradable and is permeable to the molecules to be delivered. The physical properties of the material used, its degree of crosslinking, and its thickness will determine the time necessary for the molecules to diffuse through the cap material. If diffusion out of the release system is limiting, the cap material delays the onset of release. If diffusion through the cap material is limiting, the cap material determines the release rate of the molecules in addition to delaying the onset of release.

In the active timed release devices, the reservoir caps consist of a thin film of conductive material that is deposited over the reservoir, patterned to a desired geometry, and serves as an anode. Cathodes are also fabricated on the device with their size and placement dependent on the device's application and method of electric potential control. The anode is defined as the electrode where oxidation occurs. Any conductive material capable of dissolving into solution or forming soluble ions or oxidation compounds upon application of an electric potential can be used for the fabrication of the anodes and cathodes. In addition, materials that normally form insoluble ions or oxidation products in response to an electric potential can be used if, for example, local pH changes near the anode cause these oxidation products to become soluble. Examples of suitable reservoir cap materials include metals such as copper, gold, silver, and zinc, and some polymers, as described, for example, by I.C. Kwon *et al.*, "Electrically erodible polymer gel for controlled release of drugs", *Nature*, 354:291-93

(1991); and Y.H. Bae *et al.*, "Pulsatile drug release by electric stimulus", *ACS Symposium Series*, 545: 98-110 (1994).

E. Device Packaging, Control Circuitry, and Power Source

Microelectronic device packages are typically made of an insulating or
5 dielectric material such as aluminum oxide or silicon nitride. Their purpose is to
allow all components of the device to be placed in close proximity and to
facilitate the interconnection of components to power sources and to each other.
For *in vivo* applications of the delivery device, the entire package, including all
components (i.e. the device, the microprocessor, and the power source), are
10 coated or encapsulated in a biocompatible material such as poly(ethylene glycol)
or polytetrafluoroethylene-like materials. The materials requirements for *in*
vitro applications may be less stringent and depend on the particular situation.

The control circuitry consists of a timer, a demultiplexer, a
microprocessor, and an input source, for example, a memory source, a signal
15 receiver, or a biosensor. The timer and demultiplexer circuitry can be designed
and incorporated directly onto the surface of the microchip during electrode
fabrication. The criteria for selection of a microprocessor are small size, low
power requirement, and the ability to translate the output from memory sources,
signal receivers, or biosensors into an address for the direction of power through
20 the demultiplexer to a specific reservoir on the delivery device. Selection of a
source of input to the microprocessor such as memory sources, signal receivers,
or biosensors depends on the delivery device's particular application and
whether device operation is preprogrammed, controlled by remote means, or
controlled by feedback from its environment (i.e. biofeedback).

25 The criteria for selection of a power source are small size, sufficient
power capacity, ability to be integrated into the control circuitry, the ability to be
recharged, and the length of time before recharging is necessary. Several
lithium-based, rechargeable microbatteries have been described by S.D. Jones
and J.R. Akridge, "Development and performance of a rechargeable thin-film
30 solid-state microbattery", *Journal of Power Sources*, 54:63-67 (1995); and J.B.

Bates *et al.*, "New amorphous thin-film lithium electrolyte and rechargeable microbattery", *IEEE 35th International Power Sources Symposium*, 337-39 (1992). These batteries are typically only ten microns thick and occupy 1 cm² of area. One or more of these batteries can be incorporated directly onto the
5 delivery device.

II. Methods of Making the Microchip Devices

A. Fabrication of the Reservoirs

Devices are manufactured using methods known to those skilled in the art, reviewed, for example, by Wolf *et al.* (1986), Jaeger (1988), and Madou,
10 Fundamentals of Microfabrication (CRC Press, 1997).

In a preferred method of microchip manufacture, depicted in Figures 1 and 2, passive and active devices, respectively, fabrication begins by depositing and photolithographically patterning a material, typically an insulating or dielectric material, onto the substrate to serve as an etch mask during reservoir
15 etching. Typical insulating materials for use as a mask include silicon nitride, silicon dioxide, and some polymers, such as polyimide. In a preferred embodiment, a thin film (approximately 1000-3000 Å) of low stress, silicon-rich nitride is deposited on both sides of a silicon wafer **30/300** in a Vertical Tube Reactor (VTR). Alternatively, a stoichiometric, polycrystalline silicon nitride
20 (Si₃N₄) can be deposited by Low Pressure Chemical Vapor Deposition (LPCVD), or amorphous silicon nitride can be deposited by Plasma Enhanced Chemical Vapor Deposition (PECVD). Reservoirs are patterned into the silicon nitride film on one side of the wafer **32/320** by ultraviolet photolithography and either plasma etching or a chemical etch consisting of hot phosphoric acid or
25 buffered hydrofluoric acid. The patterned silicon nitride serves as an etch mask for the chemical etching of the exposed silicon **34/340** by a concentrated potassium hydroxide solution (approximately 20-40% KOH by weight at a temperature of 75-90 °C). Alternatively, the reservoirs can be etched into the substrate by dry etching techniques such as reactive ion etching or ion beam
30 etching. These techniques are commonly used in the fabrication of

microelectronic devices, as reviewed, for example, by Wolf *et al.* (1986) and Jaeger (1988). Use of these microfabrication techniques allows the incorporation of hundreds to thousands of reservoirs on a single microchip. The spacing between each reservoir depends on its particular application and whether the device is a passive or active device. In a passive device, the reservoirs may be less than one micron apart. In an active device, the distance between the reservoirs may be slightly larger (between approximately 1 and 10 μm) due to the space occupied by the electrodes on or near each reservoir. Reservoirs can be made in nearly any shape and depth, and need not pass completely through the substrate. In a preferred embodiment, the reservoirs are etched into a (100) oriented, silicon substrate by potassium hydroxide, in the shape of a square pyramid having side walls sloped at 54° , and pass completely through the substrate (approximately 300 μm) to the silicon nitride film on the other side of the substrate, forming a silicon nitride membrane. (Here, the silicon nitride film serves as a potassium hydroxide etch stop.) The pyramidal shape allows easy filling of the reservoirs through the large opening of the reservoir (approximately 500 μm by 500 μm) on the patterned side of the substrate, release through the small opening of the reservoir (approximately 50 μm by 50 μm) on the other side of the substrate, and provides a large cavity inside the device for storing the drugs or other molecules to be delivered.

Multi-portion substrate devices can be formed simply by making two or more individual substrate portions and then bonding them to one another with the matching openings of the reservoir sections aligned. There are two main types of bonds that can be formed between substrate portions. The first are atomic-scale or molecular-scale bonds. These types of bonds usually involve the interpenetration, intermixing, or interdiffusion of atoms or molecules of one or more of the substrates at the interface between the substrate materials. A preferred method of this type of substrate bonding for use primarily with silicon or glass substrates involves using heat and/or electric voltages to enable the interdiffusion of material between the two substrates, causing a molecular-scale

bond to form at the interface between silicon, glass, and other similar materials. This anodic bonding process is well known in the art. Another embodiment of this type of bonding involves melting and re-solidification of the top layer of one or both substrates at an interface between two or more substrate portions.

5 The melted material intermixes, and upon solidification, a strong bond is formed between the substrate portions. In one embodiment, this melting and re-solidification can be caused by the brief application of a solvent (for example, methylene chloride) to the substrate, e.g., PLEXIGLAS™ (an acrylic) or LEXAN™ (polycarbonate). The second type of bonding methods involves

10 using a material other than the substrate material to form the bond. A preferred embodiment of this type of bonding includes the use of chemical adhesives, epoxies, and cements. An embodiment that could be used with UV transparent substrate materials would involve UV curable epoxy. The UV curable epoxy would be spread between the two substrate portions using a method such as spin

15 coating, the reservoirs would be aligned, and a UV light source would be used to cross-link (i.e. cure) the epoxy and bond the substrates together.

Alternatively, reservoirs also can be formed using silicon-on-insulator (SOI) techniques, such as is described in S. Renard, "Industrial MEMS on SOI," *J. Micromech. Microeng.* 10:245-249 (2000). SOI methods can be usefully

20 adapted to form reservoirs having complex reservoir shapes, for example, as shown in Figure 9b, 9c, and 9e. SOI wafers behave essentially as two substrate portions that have been bonded on an atomic or molecular-scale before any reservoirs have been etched into either portion. SOI substrates easily allow the reservoirs (or reservoir sections) on either side of the insulator layer to be etched

25 independently, enabling the reservoirs on either side of the insulator layer to have different shapes. The reservoir (portions) on either side of the insulator layer then can be connected to form a single reservoir having a complex geometry by removing the insulator layer between the two reservoirs using methods such as reactive ion etching, laser, ultrasound, or wet chemical etching.

B. Fabrication of Passive Timed Release Reservoir Caps

In Figure 1, the steps represented by **36a**, **38a**, and **40a**, are conducted using ink jet or microinjection, while represented by **36b**, **38b**, and **40b**, are conducted using spin coating. In the fabrication of passive timed release microchips, the reservoir cap material is injected with a micro-syringe **36a**, printed with an inkjet printer cartridge, or spin coated **36b** into a reservoir having the thin membrane of insulating mask material still present over the small opening of the reservoir. If injection or inkjet printing methods are used, cap formation is complete after the material is injected or printed into the reservoir **38a** and does not require further processing. If spin coating is used, the cap material is planarized by multiple spin coatings **36b**. The surface of the film is then etched by a plasma, an ion beam, or chemical etchant until the desired cap thickness is obtained **38b**. In a preferred embodiment, the insulating material used is silicon nitride and the cap material is printed into the reservoir with an inkjet cartridge filled with a solution or suspension of the cap material.

Reservoir caps control the time at which molecules are released from the reservoirs. Each reservoir cap can be of a different thickness or have different physical properties to vary the time at which each release system containing the molecules is exposed to the surrounding fluids. Injection, inkjet printing, and spin coating are the preferred methods of reservoir filling and any of these methods may be used to fill reservoirs, regardless of the reservoir's shape or size. However, injection and inkjet printing are the preferred methods of filling deep (greater than 10 μm) reservoirs or reservoirs with large openings (greater than 100 μm). For example, to obtain different cap thicknesses using injection or inkjet printing, different amounts of cap material are injected or printed directly into each individual reservoir. Spin coating is the preferred method of filling shallow (less than 10 μm) reservoirs, reservoirs that do not pass completely through the substrate, or reservoirs with small (less than 100 μm) openings. Variation in cap thickness or material by spin coating can be achieved by a repeated, step-wise process of spin coating, masking selected reservoirs,

and etching. For example, to vary cap thickness with spin coating, the cap material is spin coated over the entire substrate. Spin coating is repeated, if necessary, until the material is nearly planarized. A mask material such as photoresist is patterned to cover the cap material in all the reservoirs except one.

- 5 Plasma, ion beam, or chemical etchants are used to etch the cap material in the exposed reservoir to the desired thickness. The photoresist is then removed from the substrate. The process is repeated as a new layer of photoresist is deposited and patterned to cover the cap material in all the reservoirs except one (the exposed reservoir is not the same one already etched to its desired
- 10 thickness). Etching of the exposed cap material in this reservoir continues until the desired cap thickness is obtained. This process of depositing and patterning a mask material such as photoresist, etching, and mask removal can be repeated until each reservoir has its own unique cap thickness. The techniques, UV photolithography, plasma or ion beam etching, etc., are well known to those
- 15 skilled in the field of microfabrication.

- Although injection, inkjet printing and spin coating are the preferred methods of cap fabrication, it is understood that each reservoir can be capped individually by capillary action, by pulling or pushing the material into the reservoir using a vacuum or other pressure gradient, by melting the material into
- 20 the reservoir, by centrifugation and related processes, by manually packing solids into the reservoir, or by any combination of these or similar reservoir filling techniques.

- Once a cap fabrication method is selected, additional methods for controlling the time of release of molecules from a reservoir can be utilized, for
- 25 example, including either UV polymerizable polymers or the layering of release system and cap materials. In the first embodiment, where the reservoir caps are made of either an injected, inkjet printed or spin coated UV polymerizable polymer, each cap can be exposed to a different intensity of UV light to give varying degrees of crosslinking and therefore, different degradation or
- 30 dissolution rates for degradable caps or different permeabilities to the molecules

for non-degradable caps. Second, layers of cap material, both degradable and non-degradable, can be inserted between layers of the release system containing the molecules to be delivered by injection, inkjet printing, spin coating, or selective crosslinking. These and other similar methods allow complex release
5 profiles (e.g., pulsatile delivery at irregular time intervals) to be achieved from a single reservoir.

If desired, a passive timed release device can be fabricated without reservoir caps. The rate of release of the molecules is thus solely controlled by the physical and material properties of the release system containing the
10 molecule to be delivered.

Several possible configurations for passive delivery devices are shown in Figure 7.

C. Fabrication of Active Timed Release Reservoir Caps

In a preferred embodiment, photoresist is patterned in the form of
15 electrodes on the surface of the substrate having the reservoirs covered by the thin membrane of insulating or dielectric material. The photoresist is developed such that the area directly over the covered opening of the reservoir is left uncovered by photoresist and is in the shape of an anode. A thin film of conductive material capable of dissolving into solution or forming soluble ions
20 or oxidation compounds upon the application of an electric potential is deposited over the entire surface using deposition techniques such as chemical vapor deposition, electron or ion beam evaporation, sputtering, spin coating, and other techniques known in the art. Exemplary materials include metals such as copper, gold, silver, and zinc and some polymers, as disclosed by Kwon *et al.*
25 (1991) and Bae *et al.* (1994). After film deposition, the photoresist is stripped from the substrate. This removes the deposited film, except in those areas not covered by photoresist (lift-off technique). This leaves conducting material on the surface of the substrate in the form of electrodes 360. An alternative method involves depositing the conductive material over the entire surface of the device,
30 patterning photoresist on top of the conductive film using UV or infrared (IR)

photolithography, so that the photoresist lies over the reservoirs in the shape of anodes, and etching the unmasked conductive material using plasma, ion beam, or chemical etching techniques. The photoresist is then stripped, leaving conductive film anodes covering the reservoirs. Typical film thicknesses of the
5 conductive material may range from 0.05 to several microns. The anode serves as the reservoir cap and the placement of the cathodes on the device is dependent upon the device's application and method of electric potential control.

An insulating or dielectric material such as silicon oxide (SiO_x) or silicon nitride (SiN_x) is deposited over the entire surface of the device by
10 methods such as chemical vapor deposition (CVD), electron or ion beam evaporation, sputtering, or spin coating. Photoresist is patterned on top of the dielectric to protect it from etching except on the cathodes and the portions of the anodes directly over each reservoir 380. The dielectric material can be etched by plasma, ion beam, or chemical etching techniques. The purpose of
15 this film is to protect the electrodes from corrosion, degradation, or dissolution in all areas where electrode film removal is not necessary for release.

The electrodes are positioned in such a way that when an electric potential is applied between an anode and a cathode, the unprotected (not covered by dielectric) portion of the anode reservoir cap oxidizes to form
20 soluble compounds or ions that dissolves into solution, exposing the release system containing the molecules to the surrounding fluids. The molecules are released from the reservoir at a rate dependent upon the degradation or dissolution rate of a degradable release system or the rate of diffusion of the molecules out of or through a non-degradable release system.

25 Several possible configurations for active delivery devices are shown in Figure 8.

D. Removal of the Insulator Membrane (reservoir etch stop)

The thin membrane of insulating or dielectric material covering the reservoir used as a mask and an etch stop during reservoir fabrication must be
30 removed from the active timed release device before filling reservoir 400 and

from the passive timed release device (if the reservoir extends completely through the substrate) after filling reservoir **44**. The membrane may be removed in two ways. First, the membrane can be removed by an ion beam or reactive ion plasma. In a preferred embodiment, the silicon nitride used as the insulating material can be removed by a reactive ion plasma composed of oxygen and fluorine containing gases such as CHF₃, CF₄, or SF₆. Second, the membrane can be removed by chemical etching. For example, buffered hydrofluoric acid (BHF or BOE) can be used to etch silicon dioxide and hot phosphoric acid can be used to etch silicon nitride.

10 **E. Reservoir Filling**

The release system containing the molecules for delivery is inserted into the large opening of the reservoir by injection, inkjet printing or spin coating **40a/40b/400**. Each reservoir can contain a different molecule and dosage. Similarly, the release kinetics of the molecule in each reservoir can be varied by the choice of the release system and cap materials. In addition, the mixing or layering of release system and cap materials in each reservoir can be used to tailor the release kinetics to the needs of a particular application.

The distribution over the microchip of reservoirs filled with the release system containing the molecules to be delivered can vary depending on the medical needs of the patient or other requirements of the system. For applications in drug delivery, for example, the drugs in each of the rows can differ from each other. One row may contain a hormone and another row may contain a metabolite. Also, the release system can differ within each row to release a drug at a high rate from one reservoir and a slow rate from another reservoir. The dosages can also vary within each row. For those devices having deep (greater than 10 μm) reservoirs or reservoirs with large (greater than 100 μm) openings, differences in reservoir loading can be achieved by injection or inkjet printing of different amounts of material directly into each reservoir. Variation between reservoirs is achieved in devices having shallow (less than 10 μm) reservoirs, reservoirs that do not pass completely through the substrate, or

reservoirs with small (less than 100 μm) openings by a repeated, step-wise process of masking selected reservoirs, spin coating, and etching, as described above regarding the fabrication by spin coating of passive timed release reservoir caps. Preferably, the release system and molecules to be delivered are
5 mixed before application to the reservoirs. Although injection, inkjet printing and spin coating are the preferred methods of filling reservoirs, it is understood that each reservoir can be filled individually by capillary action, by pulling or pushing the material into the reservoir using a vacuum or other pressure gradient, by melting the material into the reservoir, by centrifugation and related
10 processes, by manually packing solids into the reservoir, or by any combination of these or similar reservoir filling techniques.

In preferred embodiments of both active and passive release devices, the reservoir openings used for filling (i.e. the openings opposite the reservoir cap end) are sealed following reservoir filling, using any of a variety of techniques
15 known in the art. For example, sealing can be provided by bonding a rigid backing plate or a thin flexible film across the opening. Alternatively, the opening can be sealed by applying a fluid material, e.g., an adhesive, which plugs the opening and hardens to form a seal. In another embodiment, a second substrate portion, e.g., of a second device, can be bonded across the reservoirs
20 openings, as shown in Figure 9.

F. Device Packaging, Control Circuitry, and Power Source

The openings through which the reservoirs of passive and active devices are filled are sealed by wafer bonding or with a waterproof epoxy or other appropriate material impervious to the surrounding fluids 44/440. For *in vitro*
25 applications, the entire unit, except for the face of the device containing the reservoirs and electrodes, is encased in a material appropriate for the system. For *in vivo* applications, the unit is preferably encapsulated in a biocompatible material such as poly(ethylene glycol) or polytetrafluoroethylene.

The mechanism for release of molecules by the active timed release
30 device does not depend on multiple parts fitted or glued together which must

retract or dislodge. Control of the time of release of each reservoir can be achieved by a preprogrammed microprocessor, by remote control, by a signal from a biosensor, or by any combination of these methods, as shown schematically in Figure 3. First, a microprocessor is used in conjunction with a source of memory such as programmable read only memory (PROM), a timer, a demultiplexer, and a power source such as a microbattery, such as is described, for example, by Jones *et al.* (1995) and Bates *et al.* (1992). The release pattern is written directly into the PROM by the user. The PROM sends these instructions to the microprocessor. When the time for release has been reached as indicated by the timer, the microprocessor sends a signal corresponding to the address (location) of a particular reservoir to the demultiplexer. The demultiplexer sends an input, such as an electric potential, to the reservoir addressed by the microprocessor. A microbattery provides the power to operate the PROM, timer, and microprocessor, and provides the electric potential input that is directed to a particular reservoir by the demultiplexer. The manufacture, size, and location of each of these components is dependent upon the requirements of a particular application. In a preferred embodiment, the memory, timer, microprocessor, and demultiplexer circuitry is integrated directly onto the surface of the chip. The microbattery is attached to the other side of the chip and is connected to the device circuitry by vias or thin wires. However, in some cases, it is possible to use separate, prefabricated, component chips for memory, timing, processing, and demultiplexing. These are attached to the backside of the miniaturized delivery device with the battery. The size and type of prefabricated chips used depends on the overall dimensions of the delivery device and the number of reservoirs. Second, activation of a particular reservoir by the application of an electric potential can be controlled externally by remote control. Much of the circuitry used for remote control is the same as that used in the preprogrammed method. The main difference is that the PROM is replaced by a signal receiver. A signal such as radio waves, microwaves, low power laser, or ultrasound is sent to the receiver by an external source, for

example, computers or ultrasound generators. The signal is sent to the microprocessor where it is translated into a reservoir address. Power is then directed through the demultiplexer to the reservoir having the appropriate address. Third, a biosensor is integrated into the microchip to detect molecules
5 in the surrounding fluids. When the concentration of the molecules reaches a certain level, the sensor sends a signal to the microprocessor to activate one or more reservoirs. The microprocessor directs power through the demultiplexer to the particular reservoir(s).

G. Electric Potential Control Methods

10 The reservoir caps of an active device are anodes that oxidize to form soluble compounds and ions when a potential is applied between the anode and a cathode. For a given electrode material and electrolyte, there exists a range of electric potentials over which these oxidation reactions are thermodynamically and kinetically favorable. In order to reproducibly oxidize and open the
15 reservoir caps of the device, the anode potential must be maintained within this favorable potential range.

There exist two primary control methods for maintaining an electrode within a specific potential range. The first method is called potentiostatic control. As the name indicates, the potential is kept constant during reservoir
20 activation. Control of the potential is typically accomplished by incorporating a third electrode into the system that has a known, constant potential, called a reference electrode. The reference electrode can take the form of an external probe whose tip is placed within one to three millimeters of the anode surface. The potential of the anode is measured and controlled with respect to the known
25 potential of a reference electrode such as a saturated calomel electrode (SCE). In a preferred embodiment of potentiostatic control, a thin film reference electrode and potential feedback controller circuitry could be fabricated directly onto the surface of the microchip. For example, a microfabricated Ag/AgCl reference electrode integrated with a microchip device would enable the device
30 to maintain the anode potential of an activated reservoir within the oxidation

regime until the reservoir was completely opened. The second method is called galvanostatic control. As the name indicates, the current is kept constant during reservoir activation. One drawback to this method of control is that there is more than one stable potential for a given current density. However, if the current density versus potential behavior is well characterized for the microchip device in a particular electrolyte system, the current density that will maintain the anode in the oxidation regime will be known. In this case, the galvanostatic method of potential control would be preferable to the potentiostatic control, because galvanostatic control does not require a reference electrode.

10 III. Applications for the Microchip Devices

Passive and active microchip devices have numerous *in vitro* and *in vivo* applications. The microchip can be used *in vitro* to deliver small, controlled amounts of chemical reagents or other molecules to solutions or reaction mixtures at precisely controlled times and rates. Analytical chemistry and medical diagnostics are examples of fields where the microchip delivery device can be used. The microchip can be used *in vivo* as a drug delivery device. The microchips can be implanted into a patient, either by surgical techniques or by injection, or can be swallowed. The microchips provide delivery of drugs to animals or persons who are unable to remember or be ambulatory enough to take medication. The microchips further provide delivery of many different drugs at varying rates and at varying times of delivery.

In a preferred embodiment, the reservoir cap enables passive timed release, not requiring a power source, of molecules. The reservoirs are capped with materials that degrade or dissolve at a known rate or have a known permeability (diffusion constant) for the molecules to be delivered. Therefore, the degradation, dissolution or diffusion characteristics of the cap material determine the time at which the release of molecules in a particular reservoir begins. In effect, the microchip provides dual control of the release of molecules by selection of the release system (rate controller) and selection of the cap material (time controller, and in some cases, rate controller).

In another preferred embodiment, the reservoir cap enables active timed release, requiring a power source, of molecules. In this embodiment, the reservoir caps consist of a thin film of conductive material that is deposited over the reservoir, patterned to a desired geometry, and serves as an anode. Cathodes are also fabricated on the device with their size and placement dependent on the device's application and method of electric potential control. Conductive materials capable of dissolving into solution or forming soluble compounds or ions upon the application of an electric potential, including metals such as copper, gold, silver, and zinc and some polymers, are used in the active timed release device. When an electric potential is applied between an anode and cathode, the conductive material of the anode above the reservoir oxidizes to form soluble compounds or ions that dissolve into solution, exposing the release system containing the molecules to be delivered to the surrounding fluids. Alternatively, the application of an electric potential can be used to create changes in local pH near the anode reservoir cap to allow normally insoluble ions or oxidation products to become soluble. This would allow the reservoir to dissolve and expose the release system to the surrounding fluids. In either case, the molecules to be delivered are released into the surrounding fluids by diffusion out of or by degradation or dissolution of the release system. The frequency of release is controlled by incorporation of a miniaturized power source and microprocessor onto the microchip. Activation of any reservoir can be achieved by preprogramming the microprocessor, by remote control, or by a signal from a biosensor.

The microchip devices and methods of fabrication thereof will be further understood by reference to the following non-limiting examples.

Example 1: Fabrication of Active Release Microchip

1) Obtain double side polished, prime grade, (100) oriented silicon wafers.

Wafer thickness = approximately 295-310 μm

2) Deposit approximately 1600-1900 Å of low stress (10:1, silicon rich) silicon

nitride on both sides of the wafers in an SVG/Thermco 7000 Series vertical tube reactor (VTR).

Gas Flows: Ammonia (NH_3) = 24 sccm

Dichlorosilane (SiH_2Cl_2) = 253 sccm

5 Temperature = 780 °C

Chamber Pressure = 268 mtorr

Deposition Rate = approximately 30 Å/min.

3) Pattern positive photoresist (PR) as squares (approximately 500 µm by 500 µm) serving as the large reservoir openings on one side of the wafers having low

10 stress silicon nitride deposited on them.

Hexamethyldisilazane deposition on both sides of the wafer

("HMDS vapor prime") in vacuum oven

approximately 30 min. at 150 °C

Photoresist (PR) Type - OCG825-20

15 PR Spin Speed and Times (for a Solitec Inc. Model 5110 spinner)

7 sec. at 500 rpm (coat)

7 sec. at 750 rpm (spread)

30 sec. at 3500 rpm (spin)

Prebake (in Blue M Model DDC-146C oven)

20 30 min. at 90 °C

Ultraviolet (UV) exposure for each wafer in the contact aligner (Karl

Suss Model MA4) with patterned mask

32 sec. at wavelength = 320 nm

Developer Type - OCG934 1:1

25 Put exposed wafers into slightly agitated, room temperature developer

Develop Time = approximately 40 seconds

Cascade Rinse = 2 min.

Rinse and Dry Wafers in Spin Rinse Dryer (SRD)

Postbake (in Blue M Model DDC-146C oven)

30 30 min. at 120 °C

- 4) Etch the VTR nitride to the underlying silicon using a plasma etcher (Plasmaquest Series II Reactor Model 145).
 - Gas Flows: Oxygen (O_2) = 2 sccm
 - Helium (He) = 15 sccm
 - Carbon Tetrafluoride (CF_4) = 15 sccm
 - Power: RF = 10 W
 - ECR = 100 W
 - Chamber Pressure = 20 mtorr
 - Temperature = 25 °C
 - Nitride Etch Rate = approximately 350 Å/min
- 5) Remove excess PR with solvents - acetone, methanol, isopropanol.
- 6) Etch the exposed silicon in aqueous potassium hydroxide (KOH) in a wet processing hood (by Semifab, Inc.).
 - Concentration = approximately 38-40% by weight
 - Temperature = approximately 85-90 °C
 - Etch Rate = approximately 1 µm/min
- 7) Post-KOH clean in a wet processing hood (by Laminaire Corp.) to avoid K^+ contamination in cleanroom.
 - Piranha Clean for 15 min.
 - Dump Rinse = 3 times
 - Hydrofluoric Acid (HF) Dip
 - 10 sec. in 50:1 water:HF solution (by volume)
 - Dump Rinse = 3 times
 - Standard RCA clean
 - Rinse and Dry in SRD
- 8) Pattern image reversal PR over the nitride membranes for subsequent gold liftoff process.
 - HMDS vapor prime in vacuum oven
 - approximately 30 min. at 150 °C
 - Photoresist Type (PR) - AZ 5214 E

PR Spin Speed and Times (for a Solitec Inc. Model 5110 spinner)

6 sec. at 500 rpm (coat)

6 sec. at 750 rpm (spread)

30 sec. at 4000 rpm (spin)

5 Prebake (in Blue M Model DDC-146C oven): 30 min. at 90 °C

Ultraviolet (UV) exposure for each wafer in the contact aligner
(Karl Suss Model MA4) with patterned mask

40 sec. at wavelength = 320 nm

Bake for 90 sec. on a metal plate in an oven at 120 °C (Blue M Model

10 DDC-146C)

UV flood exposure for each wafer in the contact aligner (Karl
Suss Model MA4) WITHOUT a patterned mask (expose entire
wafer)

Approximately 200 sec. at wavelength = 320 nm

15 Developer Type - AZ 422 MIF

Put exposed wafers into slightly agitated, room temperature developer

Develop Time = approximately 1 min. 30 sec.

Cascade Rinse = 2 min.

Rinse and Dry Wafers in Spin Rinse Dryer (SRD)

20 9) Evaporation of gold onto the image reversal PR patterned side of each wafer
using a liftoff plate (wafer holder) in an electron beam evaporator (Temescal
Semiconductor Products Model VES 2550).

Gold Deposition Rate = 5 Å/sec.

Gold Thickness = approximately 3000 Å

25 Base Pressure = approximately 5.0×10^{-7} torr

Room Temperature (no outside heating or cooling)

10) Liftoff gold layer with acetone.

11) Clean wafers with solvents - acetone, methanol, isopropanol.

12) Oxygen plasma clean (ash) in a plasma etcher (Plasmaquest Series II

30 Reactor Model 145).

- Gas Flows: $O_2 = 25$ sccm
 $He = 15$ sccm
Power: $RF = 10$ W
 $ECR = 200$ W
- 5 Chamber Pressure = 20 mtorr
Temperature = 25 °C
- 13) Deposit plasma-enhanced chemical vapor deposition (PECVD) silicon dioxide over the entire surface of the wafers having the gold electrodes on them using a PECVD chamber (Plasma-Therm 700 Series Wafer/Batch Dual Chamber
- 10 Plasma Processing System).
- Gas Flows: 2% SiH_4 in $N_2 = 400$ sccm
 $N_2O = 900$ sccm
RF Power = 20 W
Chamber Pressure = 900 mtorr
- 15 Deposition Rate = approximately 250-500 Å/min.
Temperature = 350 °C
- 14) Clean wafers with solvents - acetone, methanol, isopropanol.
- 15) Pattern PR to expose portions of the silicon dioxide covering parts of the gold electrodes.
- 20 HMDS vapor prime in vacuum oven
approximately 30 min. at 150 °C
Photoresist (PR) Type - OCG825-20
PR Spin Speed and Times (for a Solitec Inc. Model 5110 spinner)
- 25 7 sec. at 500 rpm (coat)
7 sec. at 750 rpm (spread)
30 sec. at 3500 rpm (spin)
- Prebake (in Blue M Model DDC-146C oven): 30 min. at 90 °C
Ultraviolet (UV) exposure for each wafer in the contact aligner (Karl Suss Model MA4) with patterned mask
- 30 32 sec. at wavelength = 320 nm

Developer Type - OCG934 1:1

Put exposed wafers into slightly agitated, room temperature developer

Develop Time = approximately 55 seconds

Cascade Rinse = 2 min.

5 Rinse and Dry Wafers in Spin Rinse Dryer (SRD)

Postbake (in Blue M Model DDC-146C oven): 30 min. at 120 °C

16) Etch the exposed silicon dioxide to the gold surface with a plasma etcher
(Plasmaquest Series II Reactor Model 145).

Gas Flows: He = 15 sccm

10 CF₄ = 15 sccm

Power: RF = 10 W

ECR = 100 W

Chamber Pressure = 20 mtorr

Temperature = 15 °C

15 Silicon Dioxide Etch Rate = approximately 215 Å/min.

17) Spin photoresist on the side of the wafers having the gold electrodes to
protect the electrodes during wafer dicing.

Photoresist (PR) Type - OCG825-20

PR Spin Speed and Times (for a Solitec Inc. Model 5110 spinner)

20 7 sec. at 500 rpm (coat)

7 sec. at 750 rpm (spread)

30 sec. at 3500 rpm (spin)

Prebake (in Blue M Model DDC-146C oven): 30 min. at 90 °C

18) Dice the wafers with a diesaw (Disco Automatic Dicing Saw Model DAD-
25 2H/6T).

Process yields 21 devices per 4" wafer with each device measuring

17 mm by 17 mm on a side

19) Etch the nitride membrane from the back of the devices with a plasma
etcher (Plasmaquest Series II Reactor Model 145).

30 Gas Flows: O₂ = 2 sccm

He = 15 sccm

CF₄ = 15 sccm

Power: RF = 10 W

ECR = 100 W

5 Chamber Pressure = 20 mtorr

Temperature = 25 °C

Nitride Etch Rate = approximately 350 Å/min.

20) Clean the devices with solvents and O₂ plasma.

Solvent clean - acetone, methanol, isopropanol

10 Oxygen plasma clean with a plasma etcher (Plasmaquest Series II
Reactor Model 145)

Gas Flows: O₂ = 25 sccm

He = 15 sccm

Power: RF = 10 W

15 ECR = 200 W

Chamber Pressure = 20 mtorr

Temperature = 25 °C

Fabrication of active microchip devices is complete.

20 **Example 2: Fabrication of Passive Release Microchip**

1) Obtain double side polished, prime grade, (100) oriented silicon wafers for devices having reservoirs extending completely through the wafer or single side polished, prime grade, (100) oriented silicon wafers for devices having reservoirs that do not extend completely through the wafer.

25 Wafer thickness = approximately 295-310 µm for devices with reservoirs extending completely through the wafer (devices that do not have reservoirs extending all the way through the wafer can be of any desired thickness)

2) Deposit approximately 1600-1900 Å of low stress (10:1, silicon rich) silicon
30 nitride on both sides of the wafers in an SVG/Thermco 7000 Series vertical tube

reactor (VTR).

Gas Flows: Ammonia (NH_3) = 24 sccm

Dichlorosilane (SiH_2Cl_2) = 253 sccm

Temperature = 780 °C

5 Chamber Pressure = 268 mtorr

Deposition Rate = approximately 30 Å/min.

3) Pattern positive PR as squares (approximately 500 µm by 500 µm for devices with reservoirs extending completely through the wafer or any desired dimension for devices that do not have reservoirs extending all the way through the wafer) serving as the large reservoir openings on one side of the wafers having low stress silicon nitride deposited on them.

Hexamethyldisilazane deposition on both sides of the wafer

("HMDS vapor prime") in vacuum oven

approximately 30 min. at 150 °C

15 Photoresist (PR) Type - OCG825-20

PR Spin Speed and Times (for a Solitec Inc. Model 5110 spinner)

7 sec. at 500 rpm (coat)

7 sec. at 750 rpm (spread)

30 sec. at 3500 rpm (spin)

20 Prebake (in Blue M Model DDC-146C oven)

30 min. at 90 °C

Ultraviolet (UV) exposure for each wafer in the contact aligner (Karl

Suss Model MA4) with patterned mask

32 sec. at wavelength = 320 nm

25 Developer Type - OCG934 1:1

Put exposed wafers into slightly agitated, room temperature developer

Develop Time = approximately 40 seconds

Cascade Rinse = 2 min.

Rinse and Dry Wafers in Spin Rinse Dryer (SRD)

30 Postbake (in Blue M Model DDC-146C oven): 30 min. at 120 °C

4) Etch the VTR nitride to the underlying silicon using a plasma etcher (Plasmaquest Series II Reactor Model 145).

Gas Flows: Oxygen (O_2) = 2 sccm

Helium (He) = 15 sccm

5 Carbon Tetrafluoride (CF_4) = 15 sccm

Power: RF = 10 W

ECR = 100 W

Chamber Pressure = 20 mtorr

Temperature = 25 °C

10 Nitride Etch Rate = approximately 350 Å/min.

5) Remove excess PR with solvents - acetone, methanol, isopropanol.

6) Etch the exposed silicon in aqueous potassium hydroxide (KOH) in a wet processing hood (by Semifab, Inc.).

Concentration = approximately 38-40% by weight

15 Temperature = approximately 85-90 °C

Etch Rate = approximately 1 µm/min.

7) Post-KOH clean in a wet processing hood (by Laminaire Corp.) to avoid K^+ contamination in cleanroom.

Piranha Clean for 15 min.

20 Dump Rinse = 3 times

Hydrofluoric Acid (HF) Dip

10 sec. in 50:1 water:HF solution (by volume)

Dump Rinse = 3 times

Standard RCA clean

25 Rinse and Dry in SRD

For those devices not having a nitride membrane (reservoirs not extending completely through the wafer), fabrication of passive microchip device is complete. Dice the wafer into individual devices. The reservoirs of each device are ready to be filled.

30 Alternately, for those devices having a nitride membrane (reservoirs

extend completely through the wafer), continue with the following steps.

8) Fill the reservoir using injection, inkjet printing, spin coating or another method with reservoir cap materials, release system, and molecules to be released, or any combination thereof.

5 9) Seal the reservoir openings on the side of the wafer through which the reservoirs were filled.

10) Etch the nitride membranes on the side of the wafer opposite the filling side by using a plasma etcher (Plasmaquest Series II Reactor Model 145) until the cap material or release system is reached (etch parameters may vary depending

10 on the type of cap material or release system under the nitride).

Gas Flows: Oxygen (O_2) = 2 sccm

Helium (He) = 15 sccm

Carbon Tetrafluoride (CF_4) = 15 sccm

Power: RF = 10 W

15 ECR = 100 W

Chamber Pressure = 20 mtorr

Temperature = 25 °C

Nitride Etch Rate = approximately 350 Å/min.

11) Spin photoresist on the side of the wafers having exposed cap materials or
20 release system to protect them during wafer dicing (this step may not be necessary, depending on the type of exposed cap material or release system).

Photoresist (PR) Type - OCG825-20

PR Spin Speed and Times (for a Solitec Inc. Model 5110 spinner)

7 sec. at 500 rpm (coat)

25 7 sec. at 750 rpm (spread)

30 sec. at 3500 rpm (spin)

Prebake (in Blue M Model DDC-146C oven): 30 min. at 90 °C

12) Dice the wafers with a diesaw (Disco Automatic Dicing Saw Model DAD-2H/6T).

30 Process yields 21 devices per 4" wafer with each device measuring

17 mm by 17 mm on a side

13) Clean the devices with solvents and O₂ plasma (these steps may not be necessary, depending on the type of exposed cap material or release system).

Solvent clean - acetone, methanol, isopropanol

5 Oxygen plasma clean in a plasma etcher (Plasmaquest Series II Reactor Model 145)

Gas Flows: O₂ = 25 sccm

He = 15 sccm

Power: RF = 10 W

10 ECR = 200 W

Chamber Pressure = 20 mtorr

Temperature = 25 °C

Fabrication of passive microchip device is complete.

15 **Example 3: Microchip with Passive Timed Drug Release**

A passive timed release device, microchip **10** is shown in Figure 4.

Microchip **10** is formed from substrate **14**. Reservoirs **16** are etched into substrate **14**. Positioned in reservoirs **16** is a release system containing molecules for delivery **18**. The reservoirs are capped with reservoir caps **12**.

20 The release system and the molecules for delivery **18** can vary between rows **20a**, **20b**, **20c**, and within reservoirs of each row.

Microchip **10** can be inserted into solution for *in vitro* applications or be implanted in a selected part of the body for *in vivo* applications and left to operate without requiring further attention. When exposed to the surrounding
25 fluids, reservoir caps **12** will degrade or become permeable to the release system containing molecules for delivery **18**.

Example 4: Microchip With Active Controlled Time Release

A drug delivery device that provides active timed release is shown as
30 microchip **100** in Figure 5. Microchip **100** is similar to microchip **10** except that

microchip **100** contains electrodes that provide for active timed release.

Microchip **100** is formed from substrate **160**, release system containing molecules for delivery **180**, anode reservoir caps **120**, and cathodes **140**.

Preferably, microchip **100** further includes an input source, a microprocessor, a
5 timer, a demultiplexer, and a power source (not shown). The power source provides energy to drive the reaction between selected anodes and cathodes. Upon application of a small potential between the electrodes, electrons pass from the anode to the cathode through the external circuit causing the anode material to oxidize and dissolve into the surrounding fluids, exposing the release
10 system containing the molecules for delivery **180** to the surrounding fluids. The microprocessor directs power to specific electrode pairs through a demultiplexer as directed by a PROM, remote control, or biosensor.

Another drug delivery device that provides active timed release is shown as microchip **200** in Figure 6. Microchip **200**, which includes substrate **260** and
15 release system containing molecules **280** for delivery, is similar to microchip **100**, but includes different electrode configurations. Microchip **200** illustrates that the shape, size, ratio, and placement of the anodes and cathodes can vary.

Example 5: Microchip Device Having Multi-Portion Substrate

20 Figures 9a-e illustrate several typical variations of the devices wherein two or more substrate portions are attached to one another to form, for example, a larger or composite substrate. The reservoir caps are shown generically, that is, insulator/etch mask materials, insulator overlayer materials, and anode/cathode materials are omitted from these Figures, except where a specific
25 embodiment is otherwise indicated. These devices can provide active release, passive release, or a combination thereof.

Figure 9a, for comparison, shows a “single” substrate device **500**, which has substrate **510**, in which reservoirs **520** are filled with molecules to be released **540**. Reservoirs **520** are covered by reservoir caps **530** and sealed with
30 backing plate **550** or other type of seal.

Figure 9b shows device **600** having a substrate formed of a top substrate portion **610a** bonded to bottom substrate portion **610b**. Reservoirs **620a**, in top substrate portion **610a** are in communication with reservoirs **620b** in bottom substrate portion **610b**. Reservoirs **620a/620b** are filled with molecules to be released **640** and are covered by reservoir caps **630** and sealed with backing plate **650** or other type of seal.

Figure 9c shows device **700** having a substrate formed of a top substrate portion **710a** bonded to bottom substrate portion **710b**. Top substrate portion **710a** has reservoir **720a** which is in communication with reservoir **720b** in bottom substrate portion **710b**. Reservoir **720b** is much larger than reservoir **720a** and reservoirs **720a/720b** contain molecules to be released **740**. Reservoirs **720a/720b** are filled with molecules to be released **740** and are covered by reservoir cap **730** and sealed with backing plate **750** or other type of seal.

Figure 9d shows device **800** having a substrate formed of a top substrate portion **810a** bonded to bottom substrate portion **810b**. Top substrate portion **810a** has reservoir **820a** which contains first molecules to be released **840a**. Bottom substrate portion **810b** has reservoir **820b** which contains second molecules to be released **840b**. First molecules to be released **840a** can be the same or different from second molecules to be released **840b**. Reservoir **820a** is covered by reservoir cap **830a** and sealed by reservoir cap **830b** (formed of an anode material) and partially by bottom substrate portion **810b**. Reservoir **820b** is covered by internal reservoir cap **830b** and sealed with backing plate **850** or other type of seal. Cathodes **860a** and **860b** are positioned to form an electric potential with anode reservoir cap **830b**.

In one embodiment of the device shown in Figure 9d, second molecules to be released **840b** are first released from reservoir **820b**, through or following the disintegration of reservoir cap **830b**, into reservoir **820a**, wherein the second molecules mix with first molecules to be released **840a** before the mixture of molecules is released from reservoir **820a** through or following the

disintegration of reservoir cap **830a**.

Figure 9e simply shows another reservoir shape configuration in cross-section. Substrate portions **610a/710a/810a** can be formed from the same or different materials and can have the same or different thicknesses as substrate portions **610b/710b/810b**. These substrate portions can be bonded or attached together (as described in section IIA above) after they have been individually processed (e.g., etched), or they may be formed before they have any reservoirs or other features etched or micro-machined into them (such as in SOI substrates).

10 Modifications and variations of the methods and devices described herein will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.

We claim:

1. A microchip device for the release of molecules comprising a substrate comprised of two or more substrate portions bonded together, at least two reservoirs in the substrate containing the molecules for release, and

a reservoir cap positioned on, or within a portion of, the reservoir and over the molecules, so that the molecules are released from the device by diffusion through or upon disintegration of the reservoir caps,

wherein release of the molecules from the reservoir is controlled by said diffusion through or disintegration of the reservoir cap.

2. The device of claim 1 wherein the substrate comprises an upper substrate portion adjacent the reservoir cap and a lower substrate portion distal the reservoir cap.

3. The device of claim 2 wherein a reservoir section in the upper substrate portion is in communication with a reservoir section in the lower substrate portion, the two reservoir sections forming a single reservoir.

4. The device of claim 3 wherein the reservoir section in the lower substrate portion has a volume that greater than the reservoir section in the upper substrate portion.

5. The device of claim 2 wherein the lower substrate portion is provided with an internal reservoir cap interposed between a reservoir section of the upper substrate portion and a reservoir section of the lower substrate portion, wherein release of the molecules from the reservoir section in the lower substrate portion is controlled by diffusion through or disintegration of the internal reservoir cap.

6. The device of claim 5 wherein the internal reservoir cap is disintegratable, so that the two reservoir sections form a single reservoir.

7. The device of claim 5 wherein the reservoir section of the lower substrate portion contains molecules different in quantity, type, or both quantity and type, from the molecules contained in the reservoir section of the upper

substrate portion.

8. The device of claim 1 further comprising a plurality of reservoirs comprising different types of molecules, different amounts of molecules, or combinations thereof.

9. The device of claim 1 wherein release of the molecules is controlled by a release system incorporating the molecules in the reservoir.

10. The device of claim 9 wherein at least one reservoir cap is disintegratable and the release system in a reservoir is disintegratable to release the molecules after the disintegration of the reservoir cap.

11. The device of claim 9 further comprising a cathode, a microprocessor, a timer, a demultiplexer, and a power source, wherein at least one reservoir cap is an anode, wherein upon application of an electric potential between the cathode and anode, at least one reservoir cap disintegrates, and exposes the underlying release system to the surrounding fluids.

12. The device of claim 9 wherein the release system comprises drug molecules in an excipient or diluent.

13. The device of claim 9 wherein the release system further comprises a biodegradable matrix.

14. The device of claim 1 wherein at least one reservoir cap is non-disintegratable and wherein the rate of diffusion of the molecules through the cap determines the time at which the molecules are released from the reservoirs.

15. The device of claim 1 wherein the substrate comprise three or more substrate portions bonded together.

16. A method for the delivery of molecules comprising providing at a site where the molecules are to be delivered the microchip device of claim 1, and

controlling the release of the molecules from the reservoir by said diffusion through or disintegration of the reservoir cap.

17. The method of claim 16 wherein the molecules are drugs and the device is provided at the site by implanting or injecting the microchip into a

patient.

18. The method of claim 17 wherein the molecules are a drug selected from the group consisting of nucleic acids, proteins, amino acids, polysaccharides, organic molecules, and synthetic molecules.

19. The method of claim 18 wherein the drugs are in combination with a pharmaceutically acceptable carrier.

20. The method of claim 16 wherein the molecules are diagnostic or chemical reagents.

21. The method of claim 16 wherein the molecules are released in a pulsatile or continuous manner.

22. The method of claim 16 wherein controlling the release of the molecules is performed using a release system incorporating the molecules in the reservoir.

23. The method of claim 22 wherein the release system is formed by the molecules to be released.

24. The method of claim 23 wherein at least one reservoir cap is disintegratable and the reservoir caps are positioned on the reservoirs over the release system, wherein the rate of disintegration of the reservoir cap or the rate of diffusion of the molecule through the reservoir cap determines the time at which the molecules are released from the reservoir.

25. The method of claim 23 wherein the device further comprises a cathode, a microprocessor, a timer, a demultiplexer, and a power source, wherein at least one reservoir cap is an anode, and wherein the method further comprises applying an electric potential between the cathode and anode, to oxidize the reservoir cap and expose the underlying release system to the surrounding fluids.

26. The method of claim 16 wherein at least one reservoir cap is non-disintegratable and wherein the rate of diffusion of the molecules through the cap determines the time at which the molecules are released from the reservoirs.

27. A method of fabricating the microchip device of claim 1, the method

comprising:

- providing a upper substrate portion and a lower substrate portion;
- depositing and patterning a material, for use as an etch mask, on the upper substrate portion and on the lower substrate portion;
- etching a plurality of first reservoir sections in the upper substrate portion;
- etching a plurality of second reservoir sections in the lower substrate portion, wherein the first reservoir sections correspond to the second reservoir sections; and
- bonding together the upper substrate portion and the lower substrate portion, such that the first reservoir sections are aligned with the second reservoir sections.

28. The method of claim 27 wherein the first reservoir sections are in communication with the second reservoir sections, each corresponding first and second reservoir sections together forming a single reservoir.

29. The method of claim 28 wherein the volume of the second reservoir section is greater than the volume of the first reservoir section.

30. The method of claim 27 further comprising
providing the lower substrate portion with an internal reservoir cap interposed between the first reservoir section and the second reservoir section, wherein release of the molecules from the second reservoir section is controlled by diffusion through or disintegration of the internal reservoir cap.

31. The method of claim 30 wherein the internal reservoir cap is disintegratable, so that the first and second reservoir sections together form a single reservoir.

32. The method of claim 27 wherein the device is made using a silicon-on-insulator (SOI) technique.

33. The method of claim 27 further comprising filling in a single step the first and second reservoir sections with the molecules to be released.

34. The method of claim 27 further comprising filling the first reservoir

section with a first quantity of the molecules to be released and filling the second reservoir section with a second quantity or type of the molecules to be released, wherein the filling of the first reservoir section is conducted in a separate step from filling of the second reservoir section.

35. The method of claim 33 wherein the reservoirs are filled by injection, inkjet printing, or spin coating.

36. The method of claim 27 wherein the upper substrate portion comprises a top surface and a bottom surface, wherein the material for use as an etch mask is deposited onto the top surface and the bottom surface, and wherein the first reservoir sections are etched so that the material deposited onto the lower surface serves as a membrane covering each first reservoir section.

37. The method of claim 36 further comprising depositing a thin film of conductive material over the membrane of insulating material covering each first reservoir section.

38. The method of claim 37 further comprising patterning the conductive film into electrodes so that an anode covers each membrane-covered reservoir opening and cathodes are placed on areas of the device not having reservoirs.

39. The method of claim 38 further comprising depositing a material over each electrode, except the portion of the anode directly over the reservoir and a portion of the cathode.

40. The method of claim 39 further comprising removing the membrane of insulating material from underneath the layer of conductive material covering each reservoir.

41. The method of claim 27 further comprising
providing a third substrate portion,
depositing and patterning a material, for use as an etch mask, on the third substrate portion;

etching a plurality of third reservoir sections in the third substrate portion, wherein the first reservoir sections correspond to the second reservoir


sections; and

bonding together the third substrate portion with one or both of the lower substrate portion and upper substrate portion, such that the third reservoir sections are aligned with the lower reservoir sections and upper reservoir sections.

MICROCHIP DRUG DELIVERY DEVICES

Abstract of the Disclosure

Microchip devices for the release of molecules, such as drugs, are provided which include (1) a substrate comprised of two or more substrate portions bonded together, (2) at least two reservoirs in the substrate containing the molecules for release, and (3) a reservoir cap positioned on, or within a portion of, the reservoir and over the molecules, so that the molecules are controllably released from the device by diffusion through or upon disintegration of the reservoir caps. The substrate comprises upper and lower substrate portions having first and second reservoir sections, respectively, which can be in communication with one another together, or which are provided with an internal reservoir cap interposed between the reservoir sections wherein release of the molecules from the reservoir section in the lower substrate portion is controlled by diffusion through or disintegration of the internal reservoir cap. The internal reservoir cap can be disintegratable so that the two reservoir sections thereby form a single reservoir. In the latter embodiment, the reservoir section of the lower substrate portion can contain molecules different in quantity, type, or both quantity and type, from the molecules contained in the reservoir section of the upper substrate portion. The filled reservoirs can be capped with materials that passively disintegrate, materials that allow the molecules to diffuse passively out of the reservoir over time, or materials that disintegrate upon application of an electric potential.






FIG. 2





FIG. 3







- | | |
|---|---|
|  | RELEASE SYSTEM CONTAINING THE DRUG OR
OTHER MOLECULE |
|  | RESERVOIR CAP MATERIAL |
|  | INSULATOR/ETCH MASK MATERIAL |

FIG. 4







-  RELEASE SYSTEM CONTAINING THE DRUG OR OTHER MOLECULE
-  ANODE AND CATHODE MATERIAL
-  INSULATOR/ETCH MASK MATERIAL

FIG. 5






-  RELEASE SYSTEM CONTAINING THE DRUG OR OTHER MOLECULE
-  ANODE AND CATHODE MATERIAL
-  INSULATOR OVERLAYER AND ETCH MASK MATERIAL

FIG. 6

FIG. 7a




FIG. 7e




FIG. 7b




FIG. 7f




FIG. 7c




FIG. 7g




FIG. 7d




FIG. 7h






FIG. 7i



DEGRADABLE RESERVOIR
CAP MATERIAL




NON-DEGRADABLE
RESERVOIR-CAP
MATERIAL




DEGRADABLE RELEASE
SYSTEM



NON-DEGRADABLE RELEASE SYSTEM



PURE DRUG OR OTHER MOLECULE (SOLID, LIQUID, OR
GEL FORM)



INSULATOR /ETCH MASK MATERIAL




FIG. 8a




FIG. 8b





FIG. 8c



INSULATOR / ETCH MASK MATERIAL



ANODE AND CATHODE MATERIAL




INSULATOR OVERLAYER



DEGRADABLE RELEASE SYSTEM



NON-DEGRADABLE RELEASE SYSTEM



PURE DRUG OR OTHER MOLECULE (SOLID,
LIQUID, OR GEL FORM)

Fig. 9a




Fig. 9b




Fig. 9c




Fig. 9d





Fig. 9e



Please type a plus sign (+) inside this box → +

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number MIT 6962 CIP(2)

First Named Inventor John T. Santini, Jr.

COMPLETE IF KNOWN

Application Number /

Filing Date September 19, 2000

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MICROCHIP DRUG DELIVERY DEVICES

the specification of which (Title of the Invention)

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International

Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MIT 6962 CIP(2)

Please type a plus sign (+) inside this box →



PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
U.S.S.N. 09/022,322	02/11/1998	6,123,861
U.S.S.N. 08/675,375	07/02/1996	5,797,898

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here

Name	Registration Number	Name	Registration Number
Patrea L. Pabst	31,284		
Robert A. Hodges	41,074		
Kevin W. King	42,737		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label

OR ☒ Correspondence address below

Name	Patrea L. Pabst				
Address	Arnall Golden & Gregory, LLP				
Address	2800 One Atlantic Center, 1201 West Peachtree Street				
City	Atlanta	State	GA	ZIP	30309-3450
Country	United States	Telephone	(404)873-8794	Fax	(404)873-8795

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname			
John T.		Santini, Jr.			
Inventor's Signature				Date	
Residence: City	Belmont	State	MA	Country	US
				Citizenship	US
Post Office Address	64 Winslow Road				
Post Office Address					
City	Belmont	State	MA	ZIP	02478
				Country	US

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



DECLARATION

ADDITIONAL INVENTOR(S) Supplemental Sheet Page 1 of 1

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
Michael J.				Cima			
Inventor's Signature					Date		
Residence: City		Winchester	State	MA	Country	US	Citizenship
Post Office Address		184 Mystic Valley Parkway					
Post Office Address							
City		Winchester	State	MA	ZIP	01890	Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])		Family Name or Surname					
Robert S.		Langer					
Inventor's Signature					Date		
Residence: City		Newton	State	MA	Country	US	Citizenship
Post Office Address		77 Lombard Street					
Post Office Address							
City		Newton	State	MA	ZIP	02458	Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle [if any])		Family Name or Surname					
Inventor's Signature					Date		
Residence: City			State		Country		Citizenship
Post Office Address							
Post Office Address							
City			State		ZIP		Country

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

MIT 6962 CIP(2)